AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
174 hedge funds and large institutions have $802M invested in AMAG Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 74 increasing their positions, 58 reducing their positions, and 26 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 58
9.13% more ownership
Funds ownership: 118.29% → 127.42% (+9.1%)
6% less funds holding
Funds holding: 185 → 174 (-11)
12% less capital invested
Capital invested by funds: $913M → $802M (-$111M)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
70% less call options, than puts
Call options by funds: $4.09M | Put options by funds: $13.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$33.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$26.6M |
| 3 |
Millennium Management
New York
|
+$22.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$22.7M |
| 5 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
+$6.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$12.6M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$10.6M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$8.09M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.93M |
| 5 |
JP Morgan Chase
New York
|
-$6.18M |
AMAG Hedge Fund Activity: Q2 2017 in Review
174 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2017, worth a combined $802M — down 12% from $913M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of AMAG and 16 opened new positions — a net loss of 10 holders — while 58 trimmed existing stakes and 74 added.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $33.7M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $12.6M sold.
- 174 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2017, down from 185 in Q1 2017.
- Funds reported $802M of AMAG Pharmaceuticals stock for Q2 2017, down 12% quarter-over-quarter.
- 16 funds opened new AMAG Pharmaceuticals positions in Q2 2017 and 26 closed out, a net change of -10 holders.
- The largest AMAG Pharmaceuticals buyer in Q2 2017 was Camber Capital Management, an estimated $33.7M added.
- The largest AMAG Pharmaceuticals seller in Q2 2017 was Perceptive Advisors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2017.